Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)

NCT06789159 is registered in ClinicalTrials.gov with Pierluigi Porcu as lead sponsor.

NCT NCT06789159
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06789159 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)
Lead sponsor
Pierluigi Porcu
Phase
Phase 1
Overall status
Recruiting
Start date
August 21, 2026
Completion date
October 1, 2028
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma refractory, diffuse large b cell lymphoma relapsed, epstein-barr virus (ebv) infection